Regeneron Pharmaceuticals REGN Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's return on invested capital?
- Regeneron Pharmaceuticals (REGN) reported return on invested capital of 10.3% in Q1 2026.
- How has Regeneron Pharmaceuticals's return on invested capital changed year-over-year?
- Regeneron Pharmaceuticals's return on invested capital decreased by 16.1% year-over-year, from 12.3% to 10.3%.
- What is the long-term trend for Regeneron Pharmaceuticals's return on invested capital?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's return on invested capital has grown at a -28.8% compound annual growth rate (CAGR), from 174.7% to 45%.
- What does return on invested capital mean?
- The after-tax return the business earns on all the capital — debt and equity — invested in it.
- How do you interpret return on invested capital?
- The cleanest measure of business quality: ROIC sustained above the cost of capital creates value, below it destroys value. Compare against WACC, not against zero.
- How does return on invested capital compare across companies?
- Highly comparable across companies as a quality screen. Sector-sensitive definitions of invested capital mean banks/insurers are best excluded.